发明授权
US07300654B2 Method of treating corneal transplant rejection in high risk keratoplasty patients
有权
在高危角膜移植术患者中治疗角膜移植排斥的方法
- 专利标题： Method of treating corneal transplant rejection in high risk keratoplasty patients
- 专利标题（中）： 在高危角膜移植术患者中治疗角膜移植排斥的方法
-
申请号： US11039144申请日： 2005-01-19
-
公开(公告)号： US07300654B2公开(公告)日： 2007-11-27
- 发明人: Stanley Wiegand , Jingtai Cao , Claus Cursiefen
- 申请人： Stanley Wiegand , Jingtai Cao , Claus Cursiefen
- 申请人地址： US NY Tarrytown
- 专利权人： Regeneron Pharmaceuticals, Inc.
- 当前专利权人： Regeneron Pharmaceuticals, Inc.
- 当前专利权人地址： US NY Tarrytown
- 代理商 Valeta Gregg, Esq.
- 主分类号： A61K38/18
- IPC分类号： A61K38/18 ; C07K14/71 ; C12N15/62
摘要：
Methods of preventing, reducing, or treating corneal transplant rejection to improve transplant survival in a high risk subject comprising administering an agent capable of blocking or inhibiting vascular endothelial growth factor (VEGF) are provided. The methods are useful for inhibiting or preventing corneal transplant rejection in a human subject who is the recipient of a transplanted cornea.